ArticleChemMedChem2026
Sustainable Synthesis of 3-(1H-Indol-3-yl)propionic Acid Derivatives with Anti-Alzheimer Activity.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
A biocatalytic approach was applied to synthesizing esters and amides derived from 2-(1H-indol-3-yl)acetic (IAA), 3-(1H-indol-3-yl)propionic (IPA), and 4-(1H-indol-3-yl)butanoic (IBA) acids. Thirty-seven derivatives were obtained through lipase catalysis in mild reaction conditions with good to excellent yields and a reduced environmental impact. The scope of the reaction was explored in terms of enzyme source, solvent, temperature, substrate-to-nucleophile and enzyme-to-substrate ratios, and substrate versatility. Ten representative derivatives were evaluated as potential anti-Alzheimer's disease (AD) agents using Caenorhabditis elegans models. Among them, octyl 3-(1H-indol-3-yl)propanoate (6e), N-butyl-3-(1H-indol-3-yl)propanamide (10a), and (S)-N-(2-hydroxypropyl)-3-(1H-indol-3-yl)propanamide (13c) emerged as the most promising candidates, demonstrating significant improvements in AD pathology, including enhanced locomotion and mitochondrial function. In addition, the obtained compounds showed no toxicity in Vero cells, making them potential lead drug candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.